Objective: A growing body of evidence suggests chronic inflammation triggers the process of endometrial carcinogenesis. Interleukin (IL) 17A is an important proinflammatory factor involved in the tumour angiogenesis processes of many solid tumours. This study aimed to characterize the function of IL17A in endometrioid-type endometrial carcinoma.

Methods: Levels of IL17A in human endometrial tissues were analysed by immunohistochemistry. proliferation and migration were analysed in Ishikawa cells treated with IL17A, using cell counting kit-8, wound healing and transwell assays. Western blots were used to analyse levels of oestrogen receptor (ER)α and ERβ proteins in Ishikawa cells treated with IL17A.

Results: IL17A levels were significantly higher in endometrial carcinoma tissues than in endometrial hyperplasic tissues. Significantly increased proliferation and migration was observed in Ishikawa cells treated with IL17A versus controls. Investigation of the molecular mechanism revealed that IL17A treatment upregulated the ERα/ERβ protein ratio in Ishikawa cells.

Conclusions: IL17A may be an important proinflammatory factor involved in promoting endometrial carcinogenesis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780559PMC
http://dx.doi.org/10.1177/0300060520950563DOI Listing

Publication Analysis

Top Keywords

ishikawa cells
16
cells treated
12
endometrial carcinoma
8
il17a
8
endometrial carcinogenesis
8
proinflammatory factor
8
factor involved
8
proliferation migration
8
treated il17a
8
endometrial
7

Similar Publications

Objective: Endometrial cancer (EC) is a malignant tumor with various histological subtypes and molecular phenotypes. The evaluation of drug resistance is important for cancer treatment. Progesterone resistance is the major challenge in EC.

View Article and Find Full Text PDF

The role of the electron transport chain (ETC) in cell proliferation control beyond its crucial function in supporting ATP generation has recently emerged. In this study, we found that, among the four ETC complexes, the complex I (CI)-mediated NAD regeneration is important for cancer cell proliferation. In cancer cells, a decrease in CI activity by RNA interference (RNAi) against NADH:ubiquinone oxidoreductase core subunit V1 (NDUFV1) arrested the cell cycle at the G/S phase, accompanying upregulation of p21 cyclin-dependent kinase inhibitor expression.

View Article and Find Full Text PDF

HIFU induces reprogramming of the tumor immune microenvironment in a pancreatic cancer mouse model.

Med Mol Morphol

January 2025

Faculty of Advanced Techno-Surgery (FATS), Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.

Article Synopsis
  • This study investigates how different HIFU methods affect tumor growth and immune responses in pancreatic cancer mice models.
  • Both continuous and trigger pulse HIFU methods effectively reduced tumor size, with the trigger pulse showing more significant results.
  • An abscopal effect was observed, indicating tumor suppression even in non-treated areas, highlighting HIFU's possible integration with immunotherapy for better cancer treatment.
View Article and Find Full Text PDF

Background And Aims: Hepatitis B virus (HBV) is prevalent worldwide and is difficult to eradicate. Current treatment strategies for chronic hepatitis B ultimately seek to achieve functional cure (FC); however, the factors contributing to FC remain unclear. We aimed to investigate the gut microbiota profiles of patients with chronic hepatitis B who achieved FC.

View Article and Find Full Text PDF

Development of chimeric antigen receptor T cells targeting cancer-expressing podocalyxin.

Regen Ther

March 2025

Department of Cancer Immunotherapy and Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of CD19-positive B-cell malignancies. However, the field is rapidly evolving to target other antigens, such as podocalyxin (PODXL), a transmembrane protein implicated in tumor progression and poor prognosis in various cancers. This study explores the potential of PODXL-targeted CAR-T cells, utilizing a cancer-specific monoclonal antibody (CasMab) technique to enhance the specificity and safety of CAR-T cell therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!